Pages that link to "Q43613003"
Jump to navigation
Jump to search
The following pages link to A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors (Q43613003):
Displayed 50 items.
- Human immunodeficiency virus & cardiovascular risk (Q22241184) (← links)
- The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications (Q24598812) (← links)
- Adverse effects of antiretroviral therapy for HIV infection (Q24617882) (← links)
- An Increased Risk of Osteoporosis during Acquired Immunodeficiency Syndrome (Q24791238) (← links)
- Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS (Q24792952) (← links)
- High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus (Q24814179) (← links)
- Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report (Q24814430) (← links)
- Antiretroviral therapy and dyslipidaemia: unlocking the code (Q25256933) (← links)
- Metabolic syndrome, diabetes, and cardiovascular risk in HIV (Q26853470) (← links)
- The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism (Q27021950) (← links)
- A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the impact of globalization (Q27498795) (← links)
- The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology (Q27932399) (← links)
- Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review (Q28220294) (← links)
- Clinical review#: Lipodystrophies: genetic and acquired body fat disorders (Q28246346) (← links)
- Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype (Q28344599) (← links)
- Metabolic effects of indinavir in healthy HIV-seronegative men (Q28366603) (← links)
- Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir (Q28372555) (← links)
- Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases (Q28378450) (← links)
- Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening (Q28485115) (← links)
- Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray study (Q28543075) (← links)
- HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus (Q28582686) (← links)
- Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine (Q28743352) (← links)
- Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional study (Q28744647) (← links)
- Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques (Q28775900) (← links)
- Side effects of HIV therapy (Q29394405) (← links)
- Novel functions of PXR in cardiometabolic disease (Q30251861) (← links)
- Ongoing trials in HIV protease inhibitors. (Q30327423) (← links)
- Managing the care of patients infected with bloodborne diseases (Q30332745) (← links)
- 'Adipaging': ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue. (Q30385053) (← links)
- Getting to 90-90-90 in paediatric HIV: What is needed? (Q30385352) (← links)
- Ultrasound-assessed perirenal fat is related to increased ophthalmic artery resistance index in HIV-1 patients (Q30480466) (← links)
- Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. (Q30762470) (← links)
- The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database (Q30771406) (← links)
- Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data (Q30795793) (← links)
- Identification of allosteric peptide agonists of CXCR4. (Q30868390) (← links)
- iMPACT3: Internet-based development and administration of utility elicitation protocols (Q30872297) (← links)
- Use of observational data in evaluating treatments: antiretroviral therapy and HIV. (Q30969932) (← links)
- Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors (Q31055878) (← links)
- Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. (Q31143771) (← links)
- The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy (Q32058552) (← links)
- Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children (Q33378805) (← links)
- Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study (Q33389734) (← links)
- Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). (Q33404972) (← links)
- The use of combination antiretroviral therapy in HIV-infected patients (Q33543115) (← links)
- The association of HIV infection with left ventricular mass/hypertrophy (Q33570964) (← links)
- HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications (Q33604216) (← links)
- A risk-benefit assessment of HIV protease inhibitors (Q33609283) (← links)
- Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. (Q33640982) (← links)
- Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults (Q33691689) (← links)
- Inpatient health services utilization among HIV-infected adult patients in care 2002-2007. (Q33699011) (← links)